Check out top investors' recommendation for ICLR
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries primarily in Ireland, the United States, and rest of Europe. It operates through two segments, Clinical Research and Central Laboratory. The Clinical Research segment specializes in strategic development, management, and analysis of programs that support various stages of clinical development process from compound selection to Phase I to IV clinical studies. Its clinical research services include investigator recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety monitoring, clinical data management, interactive voice response, electronic patient reported outcomes, medical reporting, patient registries, outcomes research, and health economics. This segment’s clinical research services also comprise marker access and commercialization services, strategic analysis and data operation, clinical pharmacology, bioanalysis, immunoassay development, pharmacokinetic and pharmacodynamic analysis, study protocol preparation, regulatory consulting, product development planning, strategic consulting, pricing and market access consulting, medical imaging, contract staffing, and electronic endpoint adjudication. The Central Laboratory segment offers various laboratory services, such as sample analyses, safety testing, microbiology, custom flow cytometry, electronic transmission of test results, and biomarker development. ICON Public Limited Company was founded in 1990 and is headquartered in Dublin, Ireland.
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Eric Coldwell Robert W. Baird & Co., Inc. Buy   Feb 15, '18     136.00  Feb 15, '19  N/A 
Donald Hooker Morgan Stanley Buy   Jan 10, '18     130.00  Jan 10, '19  N/A 
David Windley Jefferies & Co. Buy   Jan 09, '18     145.00  Jan 09, '19  N/A 
Donald Hooker Morgan Stanley Buy   Oct 16, '17     115.00  Oct 16, '18  N/A 
David Windley Jefferies & Co. Buy   Sep 11, '17     122.00  Sep 11, '18  N/A 
Eric Coldwell Robert W. Baird & Co., Inc. Buy   Aug 31, '17     120.00  Aug 31, '18  N/A 
David Windley Jefferies & Co. Buy   Jun 29, '17       Jun 29, '18  N/A 
David Windley Jefferies & Co. Buy   Jan 28, '15   57.71  68.50  Jan 28, '16  18.70% 
David Windley Jefferies & Co. Buy   Jul 31, '14   51.80  61.00  Jul 31, '15  56.10% 
David Windley Jefferies & Co. Buy   Mar 13, '14   48.00    Mar 13, '15  42.08% 
David Windley Jefferies & Co. Buy   Jul 23, '13   38.42  44.00  Jul 23, '14  24.23% 
David Windley Jefferies & Co. Buy   Mar 12, '13   31.90    Mar 12, '14  48.87%